Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 17;10(2):e0117926.
doi: 10.1371/journal.pone.0117926. eCollection 2015.

Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study

Affiliations

Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study

Julia Fiona-Maree Gilmartin et al. PLoS One. .

Abstract

Neuropsychiatric symptoms of Alzheimer's disease (AD) such as depression may be associated with pain, which according to the literature may be inadequately recognized and managed in this population. This study aimed to identify the factors associated with analgesic use in persons with AD; in particular, how AD severity, functional status, neuropsychiatric symptoms of AD, co-morbidities and somatic symptoms are associated with analgesic use. 236 community-dwelling persons with very mild or mild AD at baseline, and their caregivers, were interviewed over five years as part of the prospective ALSOVA study. Generalized Estimating Equations (GEEs) were used to estimate unadjusted and adjusted odds ratios (ORs) for the factors associated with analgesic use over a five year follow-up. The proportion of persons with AD using any analgesic was low (13.6%) at baseline and remained relatively constant during the follow-up (15.3% at Year 5). Over time, the most prevalent analgesic changed from non-steroidal anti-inflammatories (8.1% of persons with AD at Year 1) to acetaminophen (11.1% at Year 5). Depressive symptoms (measured by the Beck Depression Inventory, BDI) were independently associated with analgesic use, after effects of age, gender, education, AD severity, comorbidities and somatic symptoms were taken into account. For every one unit increase in BDI, the odds of analgesic use increased by 4% (OR = 1.04, 95% confidence interval CI = 1.02-1.07). Caregiver depressive symptoms were not statistically significantly associated with analgesic use of the person with AD. Depressive symptoms were significantly associated with analgesic use during the five year follow-up period. Possible explanations warranting investigation are that persons with AD may express depressive symptoms as painful somatic complaints, or untreated pain may cause depressive symptoms. Greater awareness of the association between depressive symptoms and analgesic use may lead to safer and more effective prescribing for these conditions.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: JM is a senior partner of ESiOR Oy, which provides health economic and outcome research services to pharmaceutical and medical device companies. SV is a paid employee of ESiOR Oy. ST is a paid employee of Oy Medfiles Ltd which is a contract research organization (CRO) providing services to pharmaceutical companies. The listed competing interests do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Adjusted probability of analgesic use in relation to depressive symptoms and level of discomfort (means and CIs) in persons with AD.
Data is presented for persons with AD. Probability was estimated using GEEs with logit link function, binomial distribution and unstructured correlation matrix. Data is adjusted for age, gender, follow-up visit, years of education, CDR-SOB and comorbidities (arthritic conditions and number of other comorbidities). A BDI score ≥30 was considered to be indicative of severe depression. n represents number of observations included in the model, both individuals who use analgesics and who do not.

References

    1. Dillon C, Serrano CM, Castro D, Leguizamón PP, Heisecke SL, et al. (2013) Behavioral symptoms related to cognitive impairment. Neuropsychiatr Dis Treat 9: 1443–1455. 10.2147/NDT.S47133 - DOI - PMC - PubMed
    1. Byrne GJ (2005) Pharmacological treatment of behavioural problems in dementia. Australian Prescriber 28: 67–70.
    1. Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, et al. (2011) Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry 26: 473–482. 10.1002/gps.2550 - DOI - PubMed
    1. Morrison RS, Siu AL (2000) A comparison of pain and its treatment in advanced dementia and cognitively intact patients with hip fracture. J Pain Symptom Manage 19: 240–248. - PubMed
    1. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D (2011) Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 343: 1–10. - PMC - PubMed

Publication types